Financial News Feed

Weaker Buy Today AGIO ranks #1690 as BUY CANDIDATE #1690 Stronger Buy

Agios Pharmaceuticals stock forecast

AGIO stock forecast

Agios (AGIO) Catches Eye: Stock Jumps 5.4%
12:40pm, Tuesday, 18'th Jun 2019
Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes....

Read more

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Read more

No summary available....

Read more

Top Health Care StocksTop Health Care Stocks JNJ 0 73 JNJ 0 73 PFE 1 00 PFE 1 00 ABT 0 10 ABT 0 10 MRK 1 78 MRK 1 78 AMGN 0 64 AMGN 0 64 Health care stocks eased somewhat this afternoon including a nearly 0 9 gain for the NYSE Health Care Index in late trade Shares of health...

Read more

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading....

Read more

No summary available....

Read more

No summary available....

Read more

IDEAYA Biosciences Files For U.S. IPO
08:30pm, Friday, 03'rd May 2019
No summary available....

Read more

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down....

Read more

AGIO earnings call for the period ending March 31, 2019....

Read more

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2019 Results Earnings Conference Call May 02, 2019, 08:00 AM ET Company Participants Kendra Adams - Vice President,...

Read more

No summary available....

Read more

– TIBSOVO ® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based on 28 Newly Diagnosed Patients from Phase 1 Study of TIBSOVO ® in Advanced Hematologic Malignancies with an IDH1 Mutation 1 – – Single Agent TIBSOVO ® Demonstrated CR Rate of 28.6% and CR+CRh Rate of 42.9% 1 – CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO ® , an isocitrate dehydrogenase-1 (IDH1) inhibitor, to include adult patients with newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy....

Read more

No summary available....

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank